- Wantai Bio reported a net loss of 144.0 million yuan for the first half of 2025.
- The company generated revenue of 843.6 million yuan during this period.
- No analyst has rated the stock as a buy.
- There are no hold ratings for Wantai Bio at the moment.
- One analyst recommends selling Wantai Bio stock.
A look at Beijing Wantai Biological Phar Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is projected to have a mixed long-term outlook based on Smartkarma Smart Scores. The company scores moderately on factors such as Value, Dividend, Growth, Resilience, and Momentum. With a balanced scoring across these key areas, Beijing Wantai Biological Phar shows potential for steady performance in the coming years.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is involved in the manufacturing of various medical products including diagnostic reagents, vaccines, and biochemical reagents. Additionally, the company produces diagnostic equipment to support its product line. Given its overall Smartkarma Smart Scores, Beijing Wantai Biological Phar is positioned for stable growth, although with room for improvement in certain areas to further enhance its long-term outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
